Afya Limited Announces Fourth Quarter and Full-Year 2024 Financial Results

Afya Limited Announces Fourth Quarter and Full-Year 2024 Financial Results

Impressive Adjusted EBITDA Margin Expansion

Expressive Cash Generation

First Dividend Announcement

NOVA LIMA, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2024. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).

Fourth Quarter 2024 Highlights

  • 4Q24 Net Revenue increased 16.3% YoY to R$849.0 million. Net Revenue excluding acquisitions increased 12.0%, reaching R$817.8 million.
  • 4Q24 Adjusted EBITDA increased 26.7% YoY reaching R$366.0 million, with an Adjusted EBITDA Margin of 43.1%. Adjusted EBITDA Margin increased 350 bps YoY. Adjusted EBITDA excluding acquisitions grew 20.5%, reaching R$348.1 million, with an Adjusted EBITDA Margin of 42.6%.
  • 4Q24 Net Income increased 51.4% YoY, reaching R$154.3 million, and Adjusted Net Income increased 17.7% YoY, reaching R$193.6 million. Basic EPS growth was 52.4% in the same period.

Full Year 2024 Highlights

  • FY24 Net Revenue increased 14.9% YoY to R$3,304.3 million. Net Revenue excluding acquisitions grew 12.7%, reaching R$3,240.7 million.
  • FY24 Adjusted EBITDA increased 24.9% YoY reaching R$1,455.6 million, with an Adjusted EBITDA Margin of 44.1%. Adjusted EBITDA Margin increased 360 bps YoY. Adjusted EBITDA excluding acquisitions grew 21.7%, reaching R$1,418.8 million, with an Adjusted EBITDA Margin of 43.8%.
  • FY24 Net Income increased 60.1% YoY, reaching R$648.9 million, and Adjusted Net Income increased 38.8% YoY, reaching R$820.3 million. Basic EPS growth was 62.9% in the same period.
  • Operating Cash Conversion ratio of 102.2%, with a solid cash position of R$911.0 million.
  • Over 313 thousand users in Afya’s ecosystem.
Table 1: Financial Highlights
Three months period ended December 31, Twelve months period ended December 31,
(in thousand of R$)

2024

2024 Ex Acquisitions*

2023

% Chg

% Chg Ex Acquisitions

 

2024

2024 Ex Acquisitions*

2023

% Chg

% Chg Ex Acquisitions

(a) Net Revenue

849,015

817,793

729,866

16.3%

12.0%

3,304,329

3,240,686

2,875,913

14.9%

12.7%

(b) Adjusted EBITDA 2

366,014

348,147

288,912

26.7%

20.5%

1,455,642

1,418,751

1,165,678

24.9%

21.7%

(c) = (b)/(a) Adjusted EBITDA Margin

43.1%

42.6%

39.6%

350 bps 300 bps

44.1%

43.8%

40.5%

360 bps 330 bps
Net income

154,279

101,886

51.4%

648,920

405,416

60.1%

Adjusted Net income

193,607

164,449

17.7%

820,290

591,124

38.8%

*For the Three months period ended December 31, 2024, “2024 Ex Acquisitions” excludes: UNIDOM (October to December, 2024; Closing of UNIDOM was in July 2024).
*For the Twelve months period ended December 31, 2024, “2024 Ex Acquisitions” excludes: UNIDOM (July to December, 2024; Closing of UNIDOM was in July 2024).
(2) See more information on “Non-GAAP Financial Measures” (Item 08).

Message from Management

We proudly present another year of strong operational and financial performance, reflecting the differentials of our business model and the successful execution of our strategy. We closed the year with significant growth in net revenue and adjusted EBITDA delivering the guidance for 2024. These results underscore the strength of our ecosystem, which integrates Medical Education and Medical Practice Solutions to support the entire physician journey, from undergraduate studies to professional practice.

Our margin expansion was primarily driven by the integration of UNIMA and FCM Jaboatão, completed in 4Q23, the continued ramp-up of the four Mais Médicos campuses launched in 3Q22, the operational restructuring in Continuing Education and Medical Practice Solutions, the acquisition of Unidom, and our efforts to control Selling, General and Administrative expenses.

Furthermore, this year we maintained and reinforced our strategy to consolidate our leadership in providing access to quality medical education in Brazil. This was achieved through the acquisition of Unidom, which added 300 new medical school seats in Salvador, the approval of 80 additional seats at UNIMA Alagoas and 40 at Guanambi, and the reconsideration of 10 seats at Unigranrio in Rio de Janeiro. We also expanded our footprint by signing the acquisition of FUNIC, which will add 60 medical school seats in Contagem, a strategic location in the metropolitan area of Belo Horizonte. With these additions, we will reach 3,653 approved medical school seats.

We believe that sustainable growth is achieved through operational efficiency and academic excellence. In this regard, we successfully carried out a highly competitive student intake keeping the discipline of tuition adjustment above inflation, for new medical students, reflecting the strength of Afya’s brand and its reputation within the medical and health community. Additionally, we reinforced our Continuing Education and Medical Practice Solutions strategy by launching five new specialization campuses in 2024 and consolidating our Medical Practice Solutions offerings.

Financially, we maintained robust cash ensuring liquidity to sustain our strategic investments and growth initiatives. Because of our strong cash generation, we are really pleased to announce that we will return part of it as dividends to our investors while maintaining our organic and inorganic growth plans. The Board of Directors has approved a cash dividend payout of 20% of 2024 net income, reflecting our confidence in Afya’s sustainable results.

These outstanding results enabled another year of guidance achievement and reflect Afya’s consistent growth and operational excellence. This consistency added to another strong intake cycle, pave the foundation for our 2025 guidance: Net Revenue is expected to range between R$ 3,670 million and R$3,770 million, while Adjusted EBITDA is anticipated to be between R$1,620 million and R$1,720 million, excluding any acquisition that may be concluded after the issuance of the guidance. Once again, we are guiding another strong round ahead and proving AFYA´s resilience and ability to keep delivering solid results with a high predictability.

We also take immense pride in the significant social impact generated by Afya’s investments in medical education. This commitment led us to calculate our Social Return on Investment (SROI) using robust, globally recognized methodologies. According to our SROI study, every R$1 we invested resulted in R$3.58 in social benefits for the population of the municipalities analyzed. This reflects reduced mortality, increased life expectancy, and positive economic impacts such as wage growth and local financial activity.

We reaffirm our mission of transforming healthcare through education and technology, offering innovative solutions for developing and training physicians across Brazil. And that is why we are very excited to welcome Dr. Gustavo Meirelles as the Chief Medical Officer (CMO) of Afya. One of his top priorities will be driving innovation, evolving our products, and strengthening relationships within the health industry. With over 25 years of experience as a radiologist, healthcare executive, and entrepreneur, Dr. Meirelles has a proven track record in leadership, research, and consultancy, focusing on transformative changes in healthcare.

We appreciate the trust of our employees, students, partners, and shareholders. Together, we will continue driving the future of the medical journey in Brazil.

1. Key Events in the Quarter

  • On December 19th, 2024, Afya announced that it has entered into a share purchase agreement to acquire 100% of the total share capital of Faculdade Masterclass Ltda. (“Faculdade Única de Contagem” or “FUNIC”) at Contagem, State of Minas Gerais. The acquisition will add 60 medical school seats to Afya.

The aggregate purchase price is R$100 million, and the Net Debt will be deducted at closing. The price and payment conditions are R$60 million to be paid in cash at the closing date, and R$40 million to be paid in three annual installments adjusted by the Brazilian interbank interest rates (CDI).

Furthermore, there is a potential for 60 additional seats. If approved by the Ministry of Education (MEC) within 36 months from the closing date, it will result in an additional payment of R$1 million per granted seat, limited to 60 seats.

Afya expects an EV/EBITDA of 3.3x at full maturity and post synergies in 2030 with expected Net Revenue of R$52.4 million, of which 100% will come from medicine. With the acquisition, Afya will achieve 3,653 total approved seats.

2. Subsequent Event

  • On March 12, 2025, Afya’s Board declared a cash dividend of R$129.8 million, representing 20% of the Company’s consolidated net income of R$648.9 million for the year ended December 31, 2024. This amounts to a dividend per share (DPS) of R$1.348923, payable in U.S. dollars on April 4, 2025, to shareholders of record as of the close of business on March 26, 2025. The payment will be made at the exchange rate (PTAX) published on March 13th, 2025 by the Brazilian Central Bank, which is R$/USD 5.8131.

3. Full Year 2024 Guidance Achievement

The Company’s financial results reaffirmed the resiliency and predictability of Afya’s business model.

Guidance for 2024 Actual 2024
Net Revenue 1 R$ 3,225 mn ≤ ∆ ≤ R$ 3,325 mn R$ 3,304 mn
Adjusted EBITDA R$ 1,375 mn ≤ ∆ ≤ R$ 1,475 mn R$ 1,456 mn
CAPEX 2 R$ 220 mn ≤ ∆ ≤ R$ 260 mn R$ 235 mn
(1) Excludes any acquisition that may be concluded after the issuance of the guidance, notably, the Unidom acquisition was included in the guidance provided.
(2) The 2024 Capex guidance does not encompass the earn-out payment in the amount of R$49.6 million related to the 40-seat increase at Faculdades Integradas Padrão (FIP Guanambi), and also excludes the earn-out payment due to UNIMA Alagoas for the 80-seat increase in July 2024.

4. 2025 Guidance

The guidance for FY2025 is defined in the following table:

Guidance for 2025
Net Revenue 1 R$ 3,670 mn ≤ ∆ ≤ R$ 3,770 mn
Adjusted EBITDA R$ 1,620 mn ≤ ∆ ≤ R$ 1,720 mn
CAPEX R$ 250 mn ≤ ∆ ≤ R$ 290 mn
(1) Excludes any acquisition that may be concluded after the issuance of the guidance, notably excluding Funic.

5. 4Q24 and 2024 Overview

Segment Information

The Company has three reportable segments as follows:

Undergrad, which provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs;

Continuing education, which provides medical education (including residency preparation programs, specialization test preparation and other medical capabilities), specialization and graduate courses in medicine, delivered through digital and in-person content; and

Medical Practice Solutions, which provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

Key Revenue Drivers – Undergraduate Programs

Table 2: Key Revenue Drivers Twelve months period ended December 31,

2024

2023

% Chg

Undergrad Programs
MEDICAL SCHOOL
Approved Seats

3,593

3,163

13.6%

Operating Seats 1

3,543

3,113

13.8%

Total Students (end of period)

24,255

21,446

13.1%

Average Total Students

23,440

21,154

10.8%

Average Total Students (ex-Acquisitions)*

22,863

21,154

8.1%

Net Revenue (Total – R$ ‘000)

2,487,103

2,147,448

15.8%

Net Revenue (ex- Acquisitions* – R$ ‘000)

2,427,630

2,147,448

13.0%

Medical School Net Avg. Ticket (ex- Acquisitions* – R$/month)

8,849

8,460

4.6%

UNDERGRADUATE HEALTH SCIENCE

 

Total Students (end of period)

25,570

21,117

21.1%

Average Total Students

25,154

21,365

17.7%

Average Total Students (ex-Acquisitions)*

24,830

21,365

16.2%

Net Revenue (Total – R$ ‘000)

230,449

200,613

14.9%

Net Revenue (ex- Acquisitions* – R$ ‘000)

228,879

200,613

14.1%

OTHER EX- HEALTH UNDERGRADUATE

 

Total Students (end of period)

27,163

23,471

15.7%

Average Total Students

27,542

24,336

13.2%

Average Total Students (ex-Acquisitions)*

26,878

24,336

10.4%

Net Revenue (Total – R$ ‘000)

178,140

162,957

9.3%

Net Revenue (ex- Acquisitions* – R$ ‘000)

175,540

162,957

7.7%

Total Net Revenue

 

Net Revenue (Total – R$ ‘000)

2,895,692

2,511,018

15.3%

Net Revenue (ex- Acquisitions* – R$ ‘000)

2,832,049

2,511,018

12.8%

*For the Twelve months period ended December 31, 2024, “2024 Ex Acquisitions” excludes: UNIDOM (July to December, 2024; Closing of UNIDOM was in July 2024).
(1) The difference between approved and operating seats is ‘Cametá’. A campus for which we already have the license but haven’t started operations.

Key Revenue Drivers – Continuing Education

Table 3: Key Revenue Drivers Twelve months period ended December 31,

2024

2023

% Chg

Continuing Education 1
Total Students (end of period)
Residency Journey – Business to Physicians B2P 2

16,381

12,170

34.6%

Graduate Journey – Business to Physicians B2P

8,527

7,722

10.4%

Other Courses – B2P and Business to Business Offerings

25,613

27,188

-5.8%

Total Students (end of period)

50,521

47,080

7.3%

Net Revenue (R$ ‘000)

 

Business to Physicians – B2P

237,379

215,504

10.2%

Business to Business – B2B

18,060

20,325

-11.1%

Total Net Revenue

255,438

235,830

8.3%

(1) The figure above does not contemplate intercompany transactions
(2) ‘Content & Technology for Medical Education’ which had been reported in ‘Digital Services’ table, has been reclassified to ‘Continuing Education’

Key Revenue – Medical Practice Solutions

Table 4: Key Revenue Drivers Twelve months period ended December 31,

2024

2023

% Chg

Medical Practice Solutions 1

 

Active Payers (end of period)

 

Clinical Decision

161,283

153,541

5.0%

Clinical Management

33,735

30,061

12.2%

Total Active Payers (end of period)

195,018

183,602

6.2%

Monthly Active Users (MaU)

 

Total Monthly Active Users (MaU) – Digital Services 2

238,343

247,702

-3.8%

Net Revenue (R$ ‘000)

 

Business to Physicians – B2P

135,278

119,847

12.9%

Business to Business – B2B

26,509

20,435

29.7%

Total Net Revenue

161,787

140,282

15.3%

(1) The figure above does not contemplate intercompany transactions
(2) ‘Content & Technology for Medical Education’ is now being reported in Continuing Education table

Key Operational Drivers – Users Positively Impacted by Afya

The Users Positively Impacted by Afya represents the total number of medical students from the Undergrad segment, students from the Continuing Education and users from Medical Practice Solutions. For the fourth quarter of 2024, Afya’s ecosystem reached 313,119 users.

Table 5: Key Revenue Drivers Twelve months period ended December 31,

2024

2023

% Chg

Users Positively Impacted by Afya 1
Undergrad (Total Medical School Students – End of Period)

24,255

21,446

13.1%

Continuing Education (Total Students – End of Period)

50,521

47,080

7.3%

Medical Practice Solutions (Monthly Active Users)

238,343

247,702

-3.8%

Ecosystem Outreach

313,119

316,228

-1.0%

(1) Ecosystem outreach does not contemplate intercompany figures. Note that there may be overlap in student numbers within the data.

Seasonality of Operations

Undergrad tuition revenues are related to the intake process, and monthly tuition fees charged to students and do not significantly fluctuate during each semester.

Continuing education revenues are mostly related to: (i) monthly intakes and tuition fees on medical education, which do not have a considerable concentration in any period; (ii) Residence journey product revenues, derived from e-books transferred at a point of time, which are concentrated at in the first and last quarter of the year due to the enrollments.

Medical Practice Solutions are comprised mainly of Afya Whitebook and Afya iClinic revenues, which do not have significant fluctuations regarding seasonality.

Net Revenue

Net Revenue for the fourth quarter of 2024 was R$849.0 million, an increase of 16.3% over the same period in the prior year. Excluding acquisitions, Net Revenue in the fourth quarter increased 12.0% YoY to R$817.8 million. For the twelve-month period ending December 31, 2024, Net Revenue was R$3,304.3 million, reflecting a 14.9% increase over last year. Excluding acquisitions, Net Revenue in the twelve-month period increased by 12.7% YoY to R$3,240.7 million.

The yearly revenue increase was mainly due to higher tickets in medicine courses, the maturation of medical school seats, the addition of 40 seats at Guanambi and 80 seats at UNIMA, the reconsideration of 10 seats at Unigranrio (Rio de Janeiro), the acquisition of Unidom, and the advancement of Medical Practice Solutions and Continuing Education segments. It is worth mentioning that as seen in table two, for undergrad programs, the organic growth came from medical courses growing 13.0% YoY, and for health science increased organically 14.1% YoY.

Table 6: Revenue & Revenue Mix
(in thousands of R$) Three months period ended December 31, Twelve months period ended December 31,

2024

2024 Ex Acquisitions*

2023

% Chg

% Chg Ex Acquisitions

 

2024

2024 Ex Acquisitions*

2023

% Chg

% Chg Ex Acquisitions

Net Revenue Mix
Undergrad

739,797

708,575

627,929

17.8%

12.8%

2,895,692

2,832,049

2,511,018

15.3%

12.8%

Continuing Education

67,707

67,707

65,820

2.9%

2.9%

255,438

255,438

235,830

8.3%

8.3%

Medical Practice Solutions

44,497

44,497

37,993

17.1%

17.1%

161,787

161,787

140,282

15.3%

15.3%

Inter-segment transactions

(2,986)

(2,986)

(1,876)

59.2%

59.2%

(8,588)

(8,588)

(11,217)

-23.4%

-23.4%

Total Reported Net Revenue

849,015

817,793

729,866

16.3%

12.0%

3,304,329

3,240,686

2,875,913

14.9%

12.7%

*For the Three months period ended December 31, 2024, “2024 Ex Acquisitions” excludes: UNIDOM (October to December, 2024; Closing of UNIDOM was in July 2024).
*For the Twelve months period ended December 31, 2024, “2024 Ex Acquisitions” excludes: UNIDOM (July to December, 2024; Closing of UNIDOM was in July 2024).

Adjusted EBITDA

Adjusted EBITDA for the fourth quarter of 2024, increased by 26.7% to R$366.0 million, up from R$288.9 million in the same period of the prior year, with the Adjusted EBITDA Margin rising by 350 basis points to 43.1%. For the twelve-month period ending December 31, 2024, Adjusted EBITDA was R$1,455.6 million, an increase of 24.9% over the same period of the prior year, accompanied by an Adjusted EBITDA Margin increase of 360 basis points in the same period.

The increase in Adjusted EBITDA Margin was mainly driven by: (a) higher gross margin in the Undergrad segment; (b) the full integration of UNIMA and FCM Jaboatão, concluded in November 2023; (c) the continued ramp-up of the four Mais Médicos campuses launched in 3Q22; (d) restructuring initiatives within Continuing Education and Medical Practice Solutions; and (e) improved cost efficiency in Selling, General, and Administrative expenses.

Table 7: Reconciliation between Adjusted EBITDA and Net Income
 
(in thousands of R$) Three months period ended December 31, Twelve months period ended December 31,

2024

2023

% Chg

 

2024

2023

% Chg

Net income

154,279

101,886

51.4%

 

648,920

405,416

60.1%

Net financial result

104,698

79,661

31.4%

 

347,459

346,974

0.1%

Income taxes expense

1,083

(9,130)

n.a.

 

27,471

24,166

13.7%

Depreciation and amortization

84,206

77,339

8.9%

 

333,341

289,511

15.1%

Interest received 1

8,438

7,690

9.7%

 

43,417

33,450

29.8%

Income share associate

(2,011)

(1,824)

10.3%

 

(11,737)

(9,495)

23.6%

Share-based compensation

6,125

11,453

-46.5%

 

32,424

31,535

2.8%

Non-recurring expenses:

9,196

21,837

-57.9%

 

34,347

44,121

-22.2%

– Integration of new companies 2

7,970

8,169

-2.4%

 

25,692

28,120

-8.6%

– M&A advisory and due diligence 3

772

239

223.0%

 

3,575

12,616

-71.7%

– Expansion projects 4

454

1,873

-75.8%

 

3,022

4,409

-31.5%

– Restructuring expenses 5

6,291

n.a.

 

2,058

11,964

-82.8%

– Mandatory Discounts in Tuition Fees 6

5,265

n.a.

 

3,824

n.a.

– Gain on tax amnesty 7

n.a.

 

(16,812)

n.a.

Adjusted EBITDA

366,014

288,912

26.7%

 

1,455,642

1,165,678

24.9%

Adjusted EBITDA Margin

43.1%

39.6%

350 bps

 

44.1%

40.5%

360 bps

(1) Represents the interest received on late payments of monthly tuition fees.
(2) Consists of expenses related to the integration of newly acquired companies.
(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.
(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.
(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.
(6) Consists of mandatory discounts in tuition fees granted by state decrees, individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.
(7) On August 10, 2023, Unigranrio entered into a tax amnesty program on interest and penalties to settle a tax proceeding in respect to ISS (city tax on services) with the municipality of Rio de Janeiro, which result in a payment of R$14,819 to settle the claim. The selling shareholders of Unigranrio agreed to pay R$5,438 regarding this matter. The Company had a provision of R$53,302 and an indemnification asset from the selling shareholders of R$20,000 (in light of the indemnification clauses as defined at acquisition of Unigranrio), in respect to such tax proceeding. The difference between the provision, indemnification asset and the actual paid amount was recorded as Other income (expenses), net on the consolidated statement of income and comprehensive income.

Adjusted Net Income

Net Income for the fourth quarter of 2024, totaled R$154.3 million, reflecting a 51.4% increase YoY. Adjusted Net Income reached R$193.6 million, up 17.7% from the same period in the prior year. For the twelve-month period, Afya achieved a Net Income of R$648.9 million, marking a 60.1% increase compared to the same period in 2023, while Adjusted Net Income rose 38.8% to R$820.3 million. This growth was primarily driven by: (a) improved operational performance, and (b) a lower effective tax rate compared to the previous year.

Adjusted EPS reached R$8.91 per share for the full-year ended December 31, 2024, an increase of 39.9% YoY, supported by higher Net Income and a disciplined capital allocation strategy.

Table 8: Adjusted Net Income
(in thousands of R$) Three months period ended December 31, Twelve months period ended December 31,

2024

2023

% Chg

2024

2023

% Chg

Net income

154,279

101,886

51.4%

 

648,920

405,416

60.1%

Amortization of Intangible Assets 1

24,007

29,273

-18.0%

 

104,599

110,052

-5.0%

Share-based compensation

6,125

11,453

-46.5%

 

32,424

31,535

2.8%

Non-recurring expenses:

9,196

21,837

-57.9%

 

34,347

44,121

-22.2%

– Integration of new companies 2

7,970

8,169

-2.4%

 

25,692

28,120

-8.6%

– M&A advisory and due diligence 3

772

239

223.0%

 

3,575

12,616

-71.7%

– Expansion projects 4

454

1,873

-75.8%

 

3,022

4,409

-31.5%

– Restructuring expenses 5

6,291

n.a.

 

2,058

11,964

-82.8%

– Mandatory Discounts in Tuition Fees 6

5,265

n.a.

 

3,824

n.a.

– Gain on tax amnesty 7

n.a.

 

(16,812)

n.a.

Adjusted Net Income

193,607

164,449

17.7%

 

820,290

591,124

38.8%

Basic earnings per share – in R$ 8

1.66

1.09

52.4%

 

7.01

4.30

62.9%

Adjusted earnings per share – in R$ 9

2.10

1.79

17.4%

 

8.91

6.37

39.9%

(1) Consists of amortization of intangible assets identified in business combinations.
(2) Consists of expenses related to the integration of newly acquired companies.
(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.
(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.
(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.
(6) Consists of mandatory discounts in tuition fees granted by state decrees, individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.
(7) On August 10, 2023, Unigranrio entered into a tax amnesty program on interest and penalties to settle a tax proceeding in respect to ISS (city tax on services) with the municipality of Rio de Janeiro, which result in a payment of R$14,819 to settle the claim. The selling shareholders of Unigranrio agreed to pay R$5,438 regarding this matter. The Company had a provision of R$53,302 and an indemnification asset from the selling shareholders of R$20,000 (in light of the indemnification clauses as defined at acquisition of Unigranrio), in respect to such tax proceeding. The difference between the provision, indemnification asset and the actual paid amount was recorded as Other income (expenses), net on the consolidated statement of income and comprehensive income.
(8) Basic earnings per share: Net Income/Weighted average number of outstanding shares.
(9) Adjusted earnings per share: Adjusted Net Income attributable to equity holders of the Parent/Weighted average number of outstanding shares.

Cash and Debt Position

As of December 31, 2024, Afya’s Cash and Cash Equivalents totaled R$911.0 million, reflecting a 64.7% increase compared to December 31, 2023. Net Debt, excluding IFRS 16 impacts, reached R$1,814.9 million, in line with the same period of the previous year, despite the R$660.0 million acquisition of Unidom and the R$157.2 million earn-out payment regarding the additional seats in Guanambi and UNIMA.

For the twelve-month period ended December 31, 2024, Afya generated R$1,453.2 million in Cash Flow from Operating Activities, up from R$1,088.8 million in the same period of the previous year, an increase of 33.5% YoY, boosted by solid operational results. The Operating Cash Conversion Ratio reached 102.2%.

Table 9: Operating Cash Conversion Ratio Reconciliation Twelve months period ended December 31,
(in thousands of R$) Considering the adoption of IFRS 16

2024

2023

% Chg

(a) Net cash flows from operating activities

1,432,659

1,043,623

37.3%

(b) Income taxes paid

20,520

45,144

-54.5%

(c) = (a) + (b) Cash flow from operating activities

1,453,179

1,088,767

33.5%

 
(d) Adjusted EBITDA

1,455,642

1,165,678

24.9%

(e) Non-recurring expenses:

34,347

44,121

-22.2%

– Integration of new companies 1

25,692

28,120

-8.6%

– M&A advisory and due diligence 2

3,575

12,616

-71.7%

– Expansion projects 3

3,022

4,409

-31.5%

– Restructuring Expenses 4

2,058

11,964

-82.8%

– Mandatory Discounts in Tuition Fees 5

3,824

n.a.
– Gain on tax amnesty 6

(16,812)

n.a.
(f) = (d) – (e) Adjusted EBITDA ex- non-recurring expenses

1,421,295

1,121,557

26.7%

(g) = (c) / (f) Operating cash conversion ratio

102.2%

97.1%

510 bps
(1) Consists of expenses related to the integration of newly acquired companies.
(2) Consists of expenses related to professional and consultant fees in connection with due diligence services for M&A transactions.
(3) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.
(4) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of acquired companies.
(5) Consists of mandatory discounts in tuition fees granted by state decrees, individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.
(6) On August 10, 2023, Unigranrio entered into a tax amnesty program on interest and penalties to settle a tax proceeding in respect to ISS (city tax on services) with the municipality of Rio de Janeiro, which result in a payment of R$14,819 to settle the claim. The selling shareholders of Unigranrio agreed to pay R$5,438 regarding this matter. The Company had a provision of R$53,302 and an indemnification asset from the selling shareholders of R$20,000 (in light of the indemnification clauses as defined at acquisition of Unigranrio), in respect to such tax proceeding. The difference between the provision, indemnification asset and the actual paid amount was recorded as Other income (expenses), net on the consolidated statement of income and comprehensive income.

The table below provides additional details on the cost of debt for 2024, considering loans and financing and accounts payable to selling shareholders. Afya’s capital structure remains solid, with a conservative leveraging position and a low cost of debt. Afya’s Net Debt (excluding the effect of IFRS16) divided by the 2024 Adjusted EBITDA is 1.2x.

The holders of the convertible (SoftBank) shall have the right to redeem all or any of the outstanding convertible for cash, the Company’s common shares or a combination thereof (at the Company’s election, subject to certain conditions) with a 5% premium on or after the five-year anniversary of the original issuance date (April ,2026). The 5% premium is deemed as part of the effective interest rate and recognized on a pro-rata basis to date of the five-year anniversary of the original issuance date. The Company recognized a premium provision of R$17.0 million in the 2024 fiscal year.

Table 10: Gross Debt and Average Cost of Debt
(in millions of R$) For the closing of the twelve months period ended in December 31,
Cost of Debt
Gross Debt Duration (Years) Per year %CDI²

2024

2023

2024

2023

2024

2023

2024

2023

Loans and financing: Softbank

845

826

1.4

2.4

7.5%

6.5%

71%

50%

Loans and financing: Debentures

527

529

2.6

3.6

12.0%

15.0%

110%

114%

Loans and financing: Others

318

445

0.8

1.3

12.7%

15.0%

117%

114%

Loans and financing: IFC

505

3.8

11.3%

105%

Accounts payable to selling shareholders

531

567

3.3

0.8

10.8%

13.1%

100%

100%

Total¹| Average

2,726

2,368

2.4

2.1

10.2%

11.8%

95%

89%

(1) Total amount refers only to the “Gross Debt” columns
(2) Based on the annualized Interbank Certificates of Deposit (“CDI”) rate for the period as a reference: FY24: ~12.15% p.y. and for FY23: ~11.65% p.y.
Table 11: Cash and Debt Position
(in thousands of R$)

FY2024

FY2023

% Chg

(+) Cash and Cash Equivalents

911,015

553,030

64.7%

Cash and Bank Deposits

6,078

11,746

-48.3%

Cash Equivalents

904,937

541,284

67.2%

(-) Loans and Financing

2,195,161

1,800,775

21.9%

Current

363,554

179,252

102.8%

Non-Current

1,831,607

1,621,523

13.0%

(-) Accounts Payable to Selling Shareholders

530,772

566,867

-6.4%

Current

185,318

353,998

-47.6%

Non-Current

345,454

212,869

62.3%

(-) Other Short and Long Term Obligations

n.a.

(=) Net Debt (Cash) excluding IFRS 16

1,814,918

1,814,612

0.0%

(-) Lease Liabilities

978,336

874,569

11.9%

Current

45,580

36,898

23.5%

Non-Current

932,756

837,671

11.4%

Net Debt (Cash) with IFRS 16

2,793,254

2,689,181

3.9%

CAPEX

Capital expenditures consist of the purchase of property and equipment and intangible assets, including expenditures mainly related to the expansion and maintenance of Afya’s campuses and headquarters, leasehold improvements, and the development of new solutions in the Medical Practice Solutions and content in the Continuing Education.

For the twelve-month period ending December 31, 2024, CAPEX was R$392.6 million. Excluding the one-off effect in the first quarter of R$49.6 million regarding the earn-out of Guanambi, due to the expansion of 40 seats in January 2024, and the earn-out of UNIMA of R$107.6 million, due to the expansion of 80 seats in July 2024 the CAPEX/Net Revenue ratio would be 7.1%.

Table 12: CAPEX
(in thousands of R$) For the Twelve months period ended December 31,

2024

2023

% Chg
CAPEX

392,615

218,428

79.7%

Property and equipment

136,924

118,435

15.6%

Intanglibe assets

255,691

99,993

155.7%

– Licenses

157,227

n.a.
– Others

98,464

99,993

-1.5%

ESG Metrics

ESG commitment is an important part of Afya’s strategy and permeates the Company’s core values. Afya has been advancing year after year on its core pillars and, since 2021, ESG metrics have been disclosed in the Company’s quarterly financial results in three key metrics, Governance and Employee Management, Environmental and Social.

The 2023 Sustainability Report can be found at: https://ir.afya.com.br/annual-report/

Table 13: ESG Metrics 1, 2 & 3

4Q24

4Q23

2024

2023

# GRI Governance and Employee Management

1

405-1

Number of employees

9,717

9,680

9,717

9,680

2

405-1

Percentage of female employees

59%

58%

59%

58%

3

405-1

Percentage of female employees in the board of directors

30%

36%

30%

36%

4

102-24

Percentage of independent member in the board of directors

40%

36%

40%

36%

 

 

Environmental

5

 

Total renewable energy generated by own photovoltaic plants (MWh)

1,741,123

1,775,220

6,329,796

4,510,637

6

302-1

Total energy consumed (MWh)

6,583,497

6,845,599

24,260,662

24,036,608

7

302-1

% of renewable energy consumed from own generation

22.3%

19.3%

23.2%

16.0%

8

302-1

% of energy consumed from the power grid

34.1%

50.2%

34.8%

60.3%

9

302-1

% of energy consumed from the free market

43.6%

30.5%

42.0%

23.7%

 

 

Social

10

413-1

Number of free clinical consultations offered by Afya

248,309

154,976

846,264

586,611

11

 

Number of physicians graduated in Afya’s campuses

22,867

20,197

22,867

20,197

12

201-4

Number of students with financing and scholarship programs (FIES and PROUNI)

12,342

10,584

12,342

10,584

13

 

% students with scholarships over total undergraduate students

16.0%

16.0%

16.0%

16.0%

14

413-1

Hospital, clinics and city halls partnerships

614

649

614

649

(1) Some factors can influence in the adequate proportionality analysis of data over the years, such as: climate changes, COVID-19 pandemic effects, seasonalities, number of employees, number of students, number of active units, among others.
(2) Starting in 2Q22, previously disclosed social data were updated to consider: (a) the number of graduated physicians considering all units after its closing, and (b) partnerships related only to medical schools.
(3) The number of students with financing and scholarship programs (FIES and PROUNI) in 2023 excludes students from the Unima and FCM Jaboatão acquisition, and for 3Q24, also excludes those from the UNIDOM acquisition.

6. Conference Call and Webcast Information

When:

March 13, 2025 at 5:00 p.m. EDT.

 

Who:

Mr. Virgilio Gibbon, Chief Executive Officer

Mr. Luis André Blanco, Chief Financial Officer

Ms. Renata Costa Couto, IR Director

 

Webcast:

https://afya.zoom.us/j/98748269632

OR

Dial-in:

Brazil: +55 11 4700 9668 or +55 21 3958 7888 or +55 11 4632 2236 or +55 11 4632 2237 or +55 11 4680 6788

United States: +1 929 205 6099 or +1 253 205 0468 or +1 253 215 8782 or +1 301 715 8592 or +1 305 224 1968 or +1 309 205 3325 or +1 312 626 6799 or +1 346 248 7799 or +1 360 209 5623 or +1 386 347 5053 or +1 507 473 4847 or +1 564 217 2000 or +1 646 931 3860 or +1 669 444 9171 or +1 669 900 6833 or +1 689 278 1000 or +1 719 359 4580

Webinar ID: 987 4826 9632

Other Numbers: https://afya.zoom.us/u/aekRMRWgAp

7. About Afya Limited (Nasdaq: AFYA; B3: A2FY34)

Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career. For more information, please visit www.afya.com.br.

8. Forward – Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements other than statements of historical fact could be deemed forward-looking, including risks and uncertainties related to statements about our competition; our ability to attract, upsell and retain students; our capacity to increase tuition prices; our ability to anticipate and meet the evolving needs of students and teachers; our capacity to source and successfully integrate acquisitions; as well as general market, political, economic, and business conditions. Additionally, these statements include financial targets such as revenue, share count and IFRS and non-IFRS financial measures including gross margin, operating margin, net income (loss) per diluted share, and free cash flow. These statements are not guarantees of future performance and undue reliance should not be placed on them.

The Company assumes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances occurring after its publication, nor to incorporate new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any of these risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from those expressed or implied by the forward-looking statements we make.

Readers should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent management’s beliefs and assumptions only as of the date they are made. Further information on these and other factors that could affect the Company’s financial results is included in filings made with the United States Securities and Exchange Commission (SEC) from time to time, including the section titled “Risk Factors” in the most recent annual report on Form 20-F. These documents are available in the SEC Filings section of the investor relations section of our website at: https://ir.afya.com.br/.

9. Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements, which are prepared and presented in accordance with IFRS accounting standards as issued by the International Accounting Standards Board—IASB, Afya presents Adjusted EBITDA, Operating Cash Conversion Ratio, Adjusted Net Income and Adjusted EPS, which are non-GAAP financial measures, for the convenience of investors. A non-GAAP financial measure is generally defined as one that intends to measure financial performance but excludes or includes amounts that would not be equally adjusted in the most comparable GAAP measure.

Afya calculates Adjusted EBITDA as net income plus/minus net financial result, plus income taxes expense, plus depreciation and amortization, plus interest received on late payments of monthly tuition fees, plus share-based compensation, plus/minus income share associate, plus/minus non-recurring expenses/income. Operating Cash Conversion Ratio is calculated as the Cash flow from Operating Activities plus income taxes paid, minus/plus non-recurring expenses/income divided by Adjusted EBITDA. The calculation of Adjusted Net Income is the Net Income plus amortization of customer relationships and trademark, plus share-based compensation, plus/minus non-recurring expenses/income. The calculation of Adjusted EPS is the Adjusted Net Income minus the non-controlling interests divided by the Weighted average number of outstanding shares.

The non-GAAP supplemental financial measures are provided with the intend to help investors in assessing the overall performance of Afya’s business regarding its core operations, cash generation and profitability. The non-GAAP financial measures described in this release are not substitutes for the IFRS measures. In addition, the calculations of Adjusted EBITDA, Operating Cash Conversion Ratio, Adjusted Net Income and Adjusted EPS are not standardized financial measures and may differ from the calculations used by other companies, including competitors in the education services industry, and therefore, Afya’s measures may not be comparable to those of other companies.

10. Financial Tables

Consolidated statements of income and comprehensive income

For the years ended December 31, 2024, 2023 and 2022

(In thousands of Brazilian reais, except for earnings per share information)

 

 

2024

2023

2022

 

 

 

 

 

 

 

 

Revenue

3,304,329

2,875,913

2,329,057

Cost of services

(1,215,603)

(1,109,813)

(859,552)

Gross profit

2,088,726

1,766,100

1,469,505

 

 

 

 

Selling, general and administrative expenses

(1,069,321)

(1,014,684)

(798,153)

Other income (expenses), net

(7,292)

15,645

(7,252)

 

 

 

 

Operating income

1,012,113

767,061

664,100

 

 

 

 

Finance income

111,283

110,642

102,042

Finance expenses

(458,742)

(457,616)

(349,893)

Net finance result

(347,459)

(346,974)

(247,851)

 

 

 

 

Share of income of associate

11,737

9,495

12,184

 

 

 

 

Income before income taxes

676,391

429,582

428,433

 

 

 

 

Income taxes expenses

(27,471)

(24,166)

(35,677)

 

 

 

 

Net income

648,920

405,416

392,756

 

 

 

 

Other comprehensive income

Total comprehensive income

648,920

405,416

392,756

 

 

 

 

Income attributable to:

 

 

 

Equity holders of the parent

631,510

386,324

373,569

Non-controlling interests

17,410

19,092

19,187

 

648,920

405,416

392,756

 

 

 

Basic earnings per common share

7.01

4.30

4.14

Diluted earnings per common share

6.93

4.27

4.12

Consolidated statements of financial position

As of December 31, 2024 and 2023

(In thousands of Brazilian reais)

 

2024

2023

Assets

 

 

 

Current assets

 

Cash and cash equivalents

911,015

553,030

Trade receivables

595,898

546,438

Recoverable taxes

25,726

43,751

Other assets

57,145

 

60,287

Total current assets

1,589,784

 

1,203,506

 

Non-current assets

 

Trade receivables

35,948

 

39,485

Other assets

115,875

117,346

Investment in associate

54,442

51,834

Property and equipment

658,482

608,685

Right-of-use assets

842,219

767,609

Intangible assets

5,532,789

4,796,016

Total non-current assets

7,239,755

6,380,975

Total assets

8,829,539

7,584,481

 

Liabilities

 

Current liabilities

 

Trade payables

128,080

108,222

Loans and financing

363,554

179,252

Lease liabilities

45,580

36,898

Accounts payable to selling shareholders

185,318

353,998

Advances from customers

161,048

153,485

Labor and social obligations

208,076

192,294

Taxes payable

33,456

27,765

Income taxes payable

4,247

3,880

Other liabilities

10,836

2,773

Total current liabilities

1,140,195

1,058,567

 

Non-current liabilities

 

Loans and financing

1,831,607

1,621,523

Lease liabilities

932,756

837,671

Accounts payable to selling shareholders

345,454

212,869

Taxes payable

112,681

88,198

Provision for legal proceedings

113,521

104,361

Other liabilities

42,742

18,280

Total non-current liabilities

3,378,761

2,882,902

Total liabilities

4,518,956

3,941,469

 

Equity

 

Share capital

17

17

Additional paid-in capital

2,344,521

2,365,200

Treasury shares

(273,955)

 

(299,150)

Share-based compensation reserve

187,497

155,073

Retained earnings

2,011,875

1,380,365

Equity attributable to equity holders of the parent

4,269,955

3,601,505

Non-controlling interests

40,628

41,507

Total equity

4,310,583

3,643,012

 

Total liabilities and equity

8,829,539

7,584,481

Consolidated statements of cash flows

For the years ended December 31, 2024, 2023 and 2022

(In thousands of Brazilian reais)

 

 

2024

2023

2022

 

 

 

 

Operating activities

 

 

 

Income before income taxes

676,391

429,582

428,433

Adjustments to reconcile income before income taxes

 

 

 

Depreciation and amortization

333,341

289,511

206,220

Write-off of property and equipment

2,539

1,910

1,697

Write-off of intangible assets

244

413

25

Allowance for expected credit losses

60,894

74,552

42,708

Share-based compensation

32,424

31,535

31,274

Net foreign exchange differences

7,027

681

852

Accrued interest

254,386

285,447

200,081

Accrued interest on lease liabilities

111,966

100,849

88,571

Share of income of associate

(11,737)

(9,495)

(12,184)

Provision (reversal) for legal proceedings

5,068

(56,825)

(766)

 

 

 

 

Changes in assets and liabilities

 

 

 

Trade receivables

(97,449)

(131,336)

(129,165)

Recoverable taxes

18,107

(15,353)

(2,230)

Other assets

11,220

88,427

(1,411)

Trade payables

18,126

24,500

9,975

Taxes payable

(14,798)

3,278

(3,915)

Advances from customers

6,329

(17,892)

8,387

Labor and social obligations

8,414

31,525

21,247

Other liabilities

30,687

(42,542)

(12,811)

 

1,453,179

1,088,767

876,988

Income taxes paid

(20,520)

(45,144)

(33,089)

Net cash flows from operating activities

1,432,659

1,043,623

843,899

 

 

 

 

Investing activities

 

 

 

Acquisition of property and equipment

(136,924)

(118,435)

(168,132)

Acquisition of intangibles assets

(255,691)

(126,993)

(128,892)

Dividends received

7,501

9,900

6,754

Acquisition of non-controlling interest

(21,000)

Acquisition of subsidiaries, net of cash acquired

(627,568)

(815,005)

(277,649)

Payments of interest from acquisition of subsidiaries and intangibles

(78,931)

(71,518)

(23,550)

Net cash flows used in investing activities

(1,091,613)

(1,143,051)

(591,469)

 

 

 

 

Financing activities

 

 

 

Payments of principal of loans and financing

(128,696)

(112,630)

(1,791)

Payments of interest of loans and financing

(177,192)

(175,889)

(116,587)

Proceeds from loans and financing

491,593

5,288

496,885

Payments of principal of lease liabilities

(41,221)

(31,473)

(28,511)

Payments of interest of lease liabilities

(111,605)

(103,911)

(85,001)

Treasury shares

(12,369)

(152,317)

Proceeds from exercise of stock options

9,376

9,791

Dividends paid to non-controlling shareholders

(18,289)

(18,750)

(19,736)

Net cash flows generated (used) in financing activities

23,966

(439,943)

92,942

Net foreign exchange differences

(7,027)

(681)

(852)

Net increase (decrease) in cash and cash equivalents

357,985

(540,052)

344,520

Cash and cash equivalents at the beginning of the year

553,030

1,093,082

748,562

Cash and cash equivalents at the end of the year

911,015

553,030

1,093,082

 

Investor Relations Contact

E-mail: [email protected]

KEYWORDS: Latin America North America United States Brazil South America New York

INDUSTRY KEYWORDS: Education Health General Health Continuing Training University

MEDIA:

Logo
Logo